Intercept Pharmaceuticals Inc. (ICPT) Rating Reiterated by Wedbush
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued on Friday. They currently have a $224.00 price target on the biopharmaceutical company’s stock. Wedbush’s price objective points to a potential upside of 105.50% from the stock’s previous close.
Several other analysts have also commented on ICPT. JMP Securities reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Sunday, November 6th. Robert W. Baird reaffirmed an “outperform” rating and set a $332.00 target price on shares of Intercept Pharmaceuticals in a report on Monday. Cantor Fitzgerald reaffirmed a “sell” rating and set a $60.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, August 8th. Vetr lowered Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $81.50 target price on the stock. in a report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. dropped their target price on Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday, August 5th. Five analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $177.07.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 109.00 on Friday. The firm has a 50-day moving average price of $138.87 and a 200-day moving average price of $148.05. The company’s market cap is $2.70 billion. Intercept Pharmaceuticals has a 1-year low of $89.76 and a 1-year high of $189.39.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) EPS for the quarter, topping the consensus estimate of ($3.82) by $0.23. The firm had revenue of $4.70 million for the quarter, compared to analyst estimates of $4.77 million. Intercept Pharmaceuticals had a negative return on equity of 61.63% and a negative net margin of 3,287.95%. Intercept Pharmaceuticals’s revenue for the quarter was up 1051.1% compared to the same quarter last year. During the same period last year, the company earned ($2.10) earnings per share. On average, equities analysts expect that Intercept Pharmaceuticals will post ($15.77) EPS for the current year.
In related news, CEO Mark Pruzanski sold 35,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the transaction, the chief executive officer now owns 579,314 shares in the company, valued at $95,586,810. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CMO David Shapiro sold 3,545 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $165.08, for a total value of $585,208.60. Following the transaction, the chief marketing officer now owns 45,732 shares in the company, valued at approximately $7,549,438.56. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors boosted its stake in Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock valued at $60,030,000 after buying an additional 31,289 shares during the period. State Street Corp boosted its stake in Intercept Pharmaceuticals by 27.5% in the first quarter. State Street Corp now owns 521,407 shares of the biopharmaceutical company’s stock valued at $66,990,000 after buying an additional 112,431 shares during the period. Societe Generale acquired a new stake in Intercept Pharmaceuticals during the second quarter valued at about $1,697,000. Carmignac Gestion boosted its stake in Intercept Pharmaceuticals by 19.6% in the second quarter. Carmignac Gestion now owns 1,993,592 shares of the biopharmaceutical company’s stock valued at $284,446,000 after buying an additional 326,855 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Intercept Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 1,149,749 shares of the biopharmaceutical company’s stock valued at $164,047,000 after buying an additional 45,241 shares during the period. Hedge funds and other institutional investors own 81.82% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.